[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1116067A1 - Pharmaceutical compositions comprising imatinib and a release retardant - Google Patents

Pharmaceutical compositions comprising imatinib and a release retardant

Info

Publication number
HK1116067A1
HK1116067A1 HK08105649.6A HK08105649A HK1116067A1 HK 1116067 A1 HK1116067 A1 HK 1116067A1 HK 08105649 A HK08105649 A HK 08105649A HK 1116067 A1 HK1116067 A1 HK 1116067A1
Authority
HK
Hong Kong
Prior art keywords
imatinib
pharmaceutical compositions
release retardant
retardant
release
Prior art date
Application number
HK08105649.6A
Other languages
English (en)
Inventor
Madhav Vasanthavada
Jay Parthiban Lakshman
Wei-Qin Tong
Abu T M Serajuddin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37027884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1116067(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1116067A1 publication Critical patent/HK1116067A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/003—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C43/00—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor
    • B29C43/02—Compression moulding, i.e. applying external pressure to flow the moulding material; Apparatus therefor of articles of definite length, i.e. discrete articles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/05—Filamentary, e.g. strands
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/06—Rod-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/36—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die
    • B29C48/395—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders
    • B29C48/40—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders using two or more parallel screws or at least two parallel non-intermeshing screws, e.g. twin screw extruders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/88—Thermal treatment of the stream of extruded material, e.g. cooling
    • B29C48/911—Cooling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2001/00—Use of cellulose, modified cellulose or cellulose derivatives, e.g. viscose, as moulding material
    • B29K2001/08—Cellulose derivatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/25—Solid
    • B29K2105/251—Particles, powder or granules
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037—Other properties
    • B29K2995/0056—Biocompatible, e.g. biopolymers or bioelastomers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2995/00—Properties of moulding materials, reinforcements, fillers, preformed parts or moulds
    • B29K2995/0037—Other properties
    • B29K2995/0059—Degradable
    • B29K2995/006—Bio-degradable, e.g. bioabsorbable, bioresorbable or bioerodible

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mechanical Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
HK08105649.6A 2005-05-10 2008-05-21 Pharmaceutical compositions comprising imatinib and a release retardant HK1116067A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67960705P 2005-05-10 2005-05-10
PCT/US2006/017558 WO2006121941A2 (fr) 2005-05-10 2006-05-08 Compositions pharmaceutiques comprenant l'imatinibe et un retardateur de liberation

Publications (1)

Publication Number Publication Date
HK1116067A1 true HK1116067A1 (en) 2008-12-19

Family

ID=37027884

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08105649.6A HK1116067A1 (en) 2005-05-10 2008-05-21 Pharmaceutical compositions comprising imatinib and a release retardant

Country Status (33)

Country Link
US (2) US20080226731A1 (fr)
EP (1) EP1888040B1 (fr)
JP (1) JP5054000B2 (fr)
KR (2) KR20080007249A (fr)
CN (1) CN101175483B (fr)
AR (1) AR054114A1 (fr)
AT (1) ATE477794T1 (fr)
AU (1) AU2006244359B2 (fr)
BR (1) BRPI0608605A2 (fr)
CA (1) CA2606602C (fr)
CY (1) CY1111389T1 (fr)
DE (1) DE602006016270D1 (fr)
DK (1) DK1888040T3 (fr)
ES (1) ES2350002T3 (fr)
GT (1) GT200600194A (fr)
HK (1) HK1116067A1 (fr)
HR (1) HRP20100615T1 (fr)
IL (1) IL186925A (fr)
JO (1) JO2647B1 (fr)
MA (1) MA29463B1 (fr)
MX (1) MX2007014067A (fr)
MY (1) MY148074A (fr)
NO (1) NO20076288L (fr)
NZ (1) NZ562538A (fr)
PE (1) PE20061449A1 (fr)
PL (1) PL1888040T3 (fr)
PT (1) PT1888040E (fr)
RU (1) RU2404775C2 (fr)
SA (1) SA06270134B1 (fr)
TN (1) TNSN07417A1 (fr)
TW (1) TWI368523B (fr)
WO (1) WO2006121941A2 (fr)
ZA (1) ZA200708839B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5069463B2 (ja) 2003-04-25 2012-11-07 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス性ホスホネート類似物
PL1778251T3 (pl) 2004-07-27 2011-09-30 Gilead Sciences Inc Koniugaty fosfonianowo-nukleozydowe jako środki przeciw wirusowi HIV
ATE445392T1 (de) * 2005-08-15 2009-10-15 Siegfried Generics Int Ag Filmtablette oder granulat enthaltend ein pyridylpyrimidin
CA2662977A1 (fr) 2006-09-22 2008-03-27 Novartis Ag Procede d'optimisation de traitement de la leucemie philadelphie positive avec des inhibiteurs de tyrosine kinase abl
EP1920767A1 (fr) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Forme posologique d'Imatinib préparée à l'état fondu.
KR20090128396A (ko) * 2007-03-12 2009-12-15 닥터 레디스 레보러터리즈 리미티드 이마티니브 메실레이트
SI2305263T1 (sl) * 2007-06-07 2012-10-30 Novartis Ag Stabilizirane amorfne oblike imatinib mezilata
AU2012201613B2 (en) * 2007-06-07 2014-12-04 Novartis Ag Stabilized amorphous forms of Imatinib mesylate
WO2009028598A1 (fr) * 2007-08-31 2009-03-05 Daiichi Sankyo Company, Limited Préparation à libération prolongée et procédé de fabrication de celle-ci
WO2009042809A1 (fr) 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Compositions d'imatinib stables
WO2009094360A1 (fr) * 2008-01-23 2009-07-30 Novartis Ag Procédé d'optimisation du traitement de maladies prolifératives à médiation par récepteur à tyrosine kinase kit avec de l'imatinib
WO2009100176A2 (fr) * 2008-02-07 2009-08-13 Abbott Laboratories Forme pharmaceutique pour administration orale d’un inhibiteur de tyrosine kinase
WO2009117401A2 (fr) * 2008-03-21 2009-09-24 Elan Pharama International Limited Compositions pour la délivrance d'imatinib spécifique du site et procédés d'utilisation
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
WO2010065433A1 (fr) 2008-12-01 2010-06-10 Novartis Ag Méthode d’optimisation du traitement de la leucémie philadelphie positive avec du mésylate d’imatinib
US20130011477A1 (en) * 2010-03-29 2013-01-10 Hetero Research Foundation Stable Pharmaceutical Composition of Imatinib
WO2011161689A1 (fr) * 2010-06-21 2011-12-29 Suven Nishtaa Pharma Pvt Ltd Comprimé pharmaceutique de mésylate d'imatinib
WO2012019633A1 (fr) 2010-08-11 2012-02-16 Synthon B.V. Granulat pharmaceutique comprenant de l'imatinib mésylate
WO2012080703A1 (fr) * 2010-12-15 2012-06-21 Cipla Limited Composition pharmaceutique comprenant de l'imatinib
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) * 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
US9750700B2 (en) * 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
WO2013008253A2 (fr) * 2011-07-11 2013-01-17 Dr. Reddys Laboratories Limited Formulations d'imatinib
JP6086520B2 (ja) * 2011-08-22 2017-03-01 大原薬品工業株式会社 薬物高含有固形製剤
US20150125534A1 (en) 2011-11-24 2015-05-07 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Imatinib solid dosage forms reconstituted just before use
KR101428149B1 (ko) * 2011-12-23 2014-08-08 씨제이헬스케어 주식회사 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
JP6185559B2 (ja) * 2012-04-11 2017-08-23 ダウ グローバル テクノロジーズ エルエルシー 有機希釈剤およびセルロースエーテルを含む組成物
KR102065328B1 (ko) * 2012-04-11 2020-01-13 다우 글로벌 테크놀로지스 엘엘씨 신규한 서방출 제형
US9364546B2 (en) 2012-04-11 2016-06-14 Dow Global Technologies Llc Melt-extruded composition comprising a cellulose ether
RU2517216C2 (ru) * 2012-08-22 2014-05-27 Закрытое Акционерное Общество "БИОКАД" (ЗАО "БИОКАД") Фармацевтическая композиция иматиниба или его фармацевтически приемлемой соли, способ ее получения и способ(ы) лечения
EP3003682B1 (fr) * 2013-05-27 2019-11-20 Steerlife India Private Limited Extrudeuse et procédé pour fragmentation par fusion
WO2015004556A1 (fr) * 2013-07-09 2015-01-15 Shilpa Medicare Limited Compositions pharmaceutiques orales comprenant du mésylate d'imatinib
WO2015165975A1 (fr) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pour traiter des néoplasies myéloïdes
CN104146973B (zh) * 2014-08-14 2017-09-05 杭州华东医药集团新药研究院有限公司 一种含有甲磺酸伊马替尼组合物及其制备方法
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
SE539450C2 (en) * 2016-02-29 2017-09-26 Imatinib for use in the treatment of stroke
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
EA033102B1 (ru) * 2017-08-21 2019-08-30 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция с модифицированным отсроченным и длительным высвобождением, содержащая аспарагинаты
EP3999027A1 (fr) * 2019-07-15 2022-05-25 Intas Pharmaceuticals Ltd. Composition pharmaceutique d'imatinib
EP4255495A1 (fr) 2020-12-03 2023-10-11 Battelle Memorial Institute Compositions de nanoparticules polymères et de nanostructures d'adn et procédés d'administration non virale
WO2022216977A1 (fr) 2021-04-07 2022-10-13 Batelle Memorial Institute Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
DE10015479A1 (de) * 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
WO2002067993A1 (fr) * 2001-02-27 2002-09-06 Senju Pharmaceutical Co., Ltd. Systeme de liberation de medicament de type polymere biodegradable
DE10207586A1 (de) 2002-02-22 2003-09-11 Degussa Herstellung von N-Methyl-3-hydroxy-3-(2-thienyl)propanamin über neue carbamatgruppenhaltige Thiophenderivate als Zwischenprodukte
EP1487424B1 (fr) * 2002-03-15 2006-09-13 Novartis AG 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide pour le traitement de maladies induites par l'angiotensine ii
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1509219A1 (fr) * 2002-05-13 2005-03-02 Beth Israel Deaconess Medical Center Methodes et compositions de traitement du rejet de greffe
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
WO2006040779A2 (fr) * 2004-10-11 2006-04-20 Natco Pharma Limited Formule à matrice flottante gastrique à libération contrôlée contenant la substance imatinib
WO2006048890A1 (fr) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Forme cristalline d'imatinib mesylate et procede d'elaboration

Also Published As

Publication number Publication date
EP1888040A2 (fr) 2008-02-20
WO2006121941A2 (fr) 2006-11-16
HRP20100615T1 (hr) 2010-12-31
CA2606602A1 (fr) 2006-11-16
WO2006121941A3 (fr) 2007-01-11
IL186925A (en) 2011-11-30
PT1888040E (pt) 2010-10-28
DE602006016270D1 (de) 2010-09-30
KR20080007249A (ko) 2008-01-17
MA29463B1 (fr) 2008-05-02
NO20076288L (no) 2008-02-05
RU2007145507A (ru) 2009-06-20
CN101175483A (zh) 2008-05-07
IL186925A0 (en) 2008-02-09
PE20061449A1 (es) 2007-01-20
RU2404775C2 (ru) 2010-11-27
AR054114A1 (es) 2007-06-06
DK1888040T3 (da) 2010-11-15
GT200600194A (es) 2006-12-04
US20080226731A1 (en) 2008-09-18
MX2007014067A (es) 2008-02-07
US20140350027A1 (en) 2014-11-27
SA06270134B1 (ar) 2009-02-07
ES2350002T3 (es) 2011-01-14
JO2647B1 (en) 2012-06-17
KR101156916B1 (ko) 2012-06-21
EP1888040B1 (fr) 2010-08-18
TWI368523B (en) 2012-07-21
JP5054000B2 (ja) 2012-10-24
JP2008540531A (ja) 2008-11-20
MY148074A (en) 2013-02-28
TNSN07417A1 (en) 2009-03-17
BRPI0608605A2 (pt) 2010-01-19
CY1111389T1 (el) 2015-08-05
NZ562538A (en) 2011-03-31
ATE477794T1 (de) 2010-09-15
PL1888040T3 (pl) 2011-02-28
CA2606602C (fr) 2013-08-27
KR20100044286A (ko) 2010-04-29
AU2006244359A1 (en) 2006-11-16
AU2006244359B2 (en) 2010-12-09
TW200716205A (en) 2007-05-01
ZA200708839B (en) 2008-11-26
CN101175483B (zh) 2012-06-20

Similar Documents

Publication Publication Date Title
TWI368523B (en) Pharmaceutical compositions comprising imatinib and a release retardant
HK1244267A1 (zh) 包含(r)-n-甲基納曲酮的藥物組合物
EP1945197A4 (fr) Compositions pharmaceutiques stabilisées et à libération retardée qui comprennent un antagoniste de bêta-adrénorécepteur
ZA200801158B (en) Sustained drug release composition
EP1765283A4 (fr) Compositions pharmaceutiques
EP2056835A4 (fr) Compositions pharmaceutiques et leurs utilisations
ZA200705530B (en) Sustained release pharmaceutical formulations
GB0409703D0 (en) Pharmaceutical compositions
HK1121950A1 (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
GB0408308D0 (en) Pharmaceutical compositions
EP1885665A4 (fr) Formulations de dithiocarbamates et de phosphite
IL188352A0 (en) Pharmaceutical compositions
ZA200804103B (en) Pharmaceutical compositions
EP1802346A4 (fr) Composition pharmaceutique à libération prolongée
EP1871348A4 (fr) Compositions pharmaceutiques a liberation prolongee
IL192091A0 (en) Pharmaceutical compositions
IL186337A0 (en) Stannsoporfin compositions and administration
ZA200709692B (en) Antineoplastic compounds and pharmaceutical compositions thereof
EP1937292A4 (fr) Compositions pharmaceutiques a base de lopap et leurs utilisations
EP1901718A4 (fr) Compositions de ticlopidine à diffusion modifiée
EP1845944A4 (fr) Compositions pharmaceutiques
GB0522045D0 (en) Pharmaceutical compositions
EP1865777A4 (fr) Compositions de stannsoporfine et administration
SI1888040T1 (sl) Farmacevtski sestavki, ki obsegajo imatinib in sredstvo za upočasnitev sproščanja
EP1809298A4 (fr) Compositions pharmaceutiques neuroprotectrices contenant du spirostenol

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170508